Video Series

Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.

A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.

Jonathan Abbas, MD, compares the safety and effectiveness of different targeted agents and considerations when selecting a frontline regimen for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Natalie Evans, MD, MS, FAHA, describes a successful community awareness campaign, which she hopes will serve as a model for future advocacy efforts.

Natalie Evans, MD, MS, FAHA, raises awareness for peripheral arterial disease and highlights how minority populations are often disproportionately affected.

Shawn Kwatra, MD, dermatologist, John Hopkins University, discusses late breaking study results on the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis (PN).

Robert Gabbay, MD, PhD, discusses the early intervention at the asymptomatic stages of type 1 diabetes characterized by autoimmune antibodies and gradual blood sugar elevations.

Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early intervention and comprehensive care.

Jessica Nance, MD, MS, discusses the significance of surrogate end points, like functional assessments, in clinical trials of treatments for Duchenne muscular dystrophy and their implications for clinical benefits.

Medical experts discuss disparities in women's access to cardiovascular care, including the underrepresentation of women in clinical trials.

The panel discusses how polypharmacy impacts medication adherence and communication between pharmacists and health care providers.

A medical expert discusses treatment decision-making and modalities for ovarian cancer, including palliative care and hospice.

Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.

The panel provides an overview of the various Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment phases, highlighting the important discussion around inpatient versus outpatient care.

The panel discusses optimal strategies for screening and detecting Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients across different treatment stages.

Aaron Gerds, MD, MS, explores the future landscape of myelofibrosis with insights from the 2003 ASH Annual Meeting and Exposition (ASH 2023), and delves into anticipated data on combination therapies and ongoing trials shaping the next phase of myelofibrosis treatment.

Robert Gabbay, MD, PhD, delineates key differences between type 1 and type 2 diabetes, including autoimmune antibodies, insulin resistance, and insulin deficiency.

Jessica Nance, MD, MS, reviews the data and evidence that led to accelerated approval of delandistrogene moxeparvovec-rokl for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.

Emma Ciafaloni, MD, FAAN, dives into the latest developments in gene therapy for muscular dystrophies, focusing on Duchenne muscular dystrophy, and discusses challenges, genetic causes, and the transformative potential of gene therapies.

A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.

Pam R. Taub, MD, FACC, FASPC, highlights disparities in access to effective evidence-based therapies for minorities, emphasizing the gap between innovation and access.

Nihar Desai, MD, MPH, introduces the panel of medical professionals and moderates a discussion on disparities in cardiovascular care among minority populations.

The panel highlights the quality of life and emotional challenges faced by patients diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Vivian Tambe Ebot-Tar, PharmD, MBA, guides a discussion on the incidence of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and how payers can have the most impact through early treatment coverage.

Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. The participants also describe diverse agents in development, including their toxicity profiles.

Gain insights into valuable educational resources for patients coping with desmoid tumors, such as global consensus papers and advocacy group websites, and the significance of seeking multiple expert opinions for informed decision-making.

Delve into the impact of observing desmoid tumors and strategies for maintaining patient well-being during treatment, and learn about the importance of education, shared decision-making, and balancing conservative vs aggressive treatment.

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guidelines for monitoring myelofibrosis treatment response and delves into crucial aspects like patient impressions, physical examinations, and symptoms.

Delve into the psychosocial aspects and pain management challenges for patients with desmoid tumors as experts address anxiety, depression, and effective pain control strategies for improved quality of life.